Close

This is a StreetInsider.com Premium Only Page

Please sign-up to enjoy all the benefits of StreetInsider.com Premium or log-in if you're already a member.

Send to a Friend Font Size: Increase Decrease

Back to EXEL Stock Lookup

Exelixis (EXEL) – Hot M&A

Jun 28, 2021 06:17 AM Exelixis (EXEL) and Ipsen Report Mixed Results with Cabozantinib in Combination with Immune Checkpoint Inhibitor in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Live

Back to EXEL Stock Lookup